| Original language | English (US) |
|---|---|
| Pages (from-to) | e305-e306 |
| Journal | Journal of the American Academy of Dermatology |
| Volume | 83 |
| Issue number | 4 |
| DOIs | |
| State | Published - Oct 2020 |
ASJC Scopus subject areas
- Dermatology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Reply to : “Do IL-17 inhibitors increase risk of respiratory tract infections?”. / Wan, Marilyn T.; Shin, Daniel B.; Winthrop, Kevin L. et al.
In: Journal of the American Academy of Dermatology, Vol. 83, No. 4, 10.2020, p. e305-e306.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Reply to
T2 - “Do IL-17 inhibitors increase risk of respiratory tract infections?”
AU - Wan, Marilyn T.
AU - Shin, Daniel B.
AU - Winthrop, Kevin L.
AU - Gelfand, Joel M.
N1 - Funding Information: Funding sources: Supported in part by a grant (P30AR069589-03) from the National Institutes of Health (Dr Gelfand).Conflicts of interest: Dr Wan is supported in part by a grant from Pfizer. Dr Winthrop receives grants from Bristol-Myers Squibb and Pfizer, and is a consultant for UCB, AbbVie, Lilly, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, and Roche. Dr Gelfand served as a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, Regeneron, UCB (data safety and monitoring board), and Sanofi and Pfizer Inc, receiving honoraria; in addition, he receives research grants (to the trustees of the University of Pennsylvania) from Abbvie, Janssen, Novartis Corp, Sanofi, Celgene, Ortho Dermatologics, and Pfizer Inc, and he has received payment for CME work related to psoriasis that was supported indirectly by Eli Lilly and Company and Ortho Dermatologics. In addition, he is a copatent holder of resiquimod for treatment of cutaneous T-cell lymphoma, and he is a deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology. Dr Shin has no conflicts of interest to declare. Funding Information: Conflicts of interest: Dr Wan is supported in part by a grant from Pfizer . Dr Winthrop receives grants from Bristol-Myers Squibb and Pfizer , and is a consultant for UCB, AbbVie, Lilly, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, and Roche. Dr Gelfand served as a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, Regeneron, UCB (data safety and monitoring board), and Sanofi and Pfizer Inc, receiving honoraria; in addition, he receives research grants (to the trustees of the University of Pennsylvania) from Abbvie , Janssen , Novartis Corp , Sanofi , Celgene , Ortho Dermatologics , and Pfizer Inc , and he has received payment for CME work related to psoriasis that was supported indirectly by Eli Lilly and Company and Ortho Dermatologics. In addition, he is a copatent holder of resiquimod for treatment of cutaneous T-cell lymphoma, and he is a deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology. Dr Shin has no conflicts of interest to declare. Funding Information: Funding sources: Supported in part by a grant ( P30AR069589-03 ) from the National Institutes of Health (Dr Gelfand).
PY - 2020/10
Y1 - 2020/10
UR - http://www.scopus.com/inward/record.url?scp=85090059478&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090059478&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2020.06.1001
DO - 10.1016/j.jaad.2020.06.1001
M3 - Letter
C2 - 32622146
AN - SCOPUS:85090059478
SN - 0190-9622
VL - 83
SP - e305-e306
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 4
ER -